Can you summarize your perspective on advances in the treatment of MAC lung disease and your position on amikacin liposome inhalation suspension in patients who require intensification beyond three-drug oral treatment?

Can you summarize your perspective on advances in the treatment of MAC lung disease and your position on amikacin liposome inhalation suspension in patients who require intensification beyond three-drug oral treatment?

Can you summarize your perspective on advances in the treatment of MAC lung disease and your position on amikacin liposome inhalation suspension in patients who require intensification beyond three-drug oral treatment?


Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | NTM-Pulmonary Infection Intelligence Zone

Presenter

Antonio Catanzaro, MD

Antonio Catanzaro, MD

Professor of Medicine
Previously, Director, Tuberculosis Control
Division of Pulmonary, Critical Care, and Sleep Medicine
UC San Diego School of Medicine
San Diego, California